Semaglutide and chronic kidney disease (CKD)
The FLOW study investigated the benefits of using semaglutide in patients with chronic kidney disease (CKD) and type 2 diabetes:
- randomly assigned patients with type 2 diabetes and chronic kidney disease to receive subcutaneous semaglutide at a dose of 1.0 mg weekly or placebo
- primary outcome was major kidney disease events, a composite of the onset of kidney failure (dialysis, transplantation, or an eGFR of <15 ml per minute per 1.73 m2), at least a 50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes
- median follow-up was 3.4 years
- risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group
The study authors concluded that:
- semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease
Reference:
- Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. NEJM May 24, 2024.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.